Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
AI in colorectal cancer treatment faces challenges including data quality and privacy issues, lack of generalizability, interpretability problems, and regulatory validation…
Yes, deep learning can help doctors find breast cancer on tomosynthesis scans, matching or improving radiologist accuracy in some cases.
New treatments for triple-negative breast cancer include chemo-immunotherapy (pembrolizumab plus platinum-based chemo) and potential NY-ESO-1 targeted therapies; for…
Yes, early research shows plasma lipid panels can help detect early-stage breast cancer, with machine learning models achieving high accuracy, but they are not yet standard…
Yes, AI is being researched for breast cancer pathology, including digital pathology, deep learning for imaging, and machine learning for biomarker detection.
After anthracycline failure, trabectedin and eribulin are standard second-line options, while pazopanib is also approved in some regions. Newer agents like repotrectinib are…
A high delta-NLR, which measures the rise in neutrophil-to-lymphocyte ratio during treatment, predicts a worse prognosis for soft tissue sarcoma patients compared to those whose…
Researchers expect to find that second-line drugs like trabectedin, pazopanib, and eribulin offer options after anthracycline failure, but consistent guidelines are still lacking…
Yes, adding regional hyperthermia to chemotherapy may improve survival for extremity soft tissue sarcoma, based on a post-hoc analysis of a randomized trial.
Liver-directed therapy combined with immune checkpoint inhibitors appears most effective; tebentafusp is approved for HLA-A*02:01+ patients; other options include…
Yes, a case report describes a patient with metastatic uveal melanoma who achieved durable disease control after adding SBRT to tebentafusp, with a partial response and 35 months…
Yes, a case report shows tebentafusp plus SBRT controlled metastatic uveal melanoma for over 35 months, but more research is needed to confirm this approach.
Immunoembolization shows lower disease control rates than the FOCUS trial for liver-dominant metastatic uveal melanoma, though tebentafusp combined with radiotherapy may offer…
ATRA plus ATO for APL achieves 3-year overall survival of 95% and 10-year survival of ≥80%, with complete remission rates over 95%.
Becotatug vedotin showed a 20.9% objective response rate in recurrent or metastatic head and neck squamous cell carcinoma after prior therapy.
Yes, different receptor types in metastatic breast cancer lesions are linked to different survival times, with hormone receptor-positive subtypes generally having longer survival…
Receptor discordance in metastatic breast cancer is linked to worse overall survival, especially when hormone receptors are lost.
Yes, hospital-acquired infections significantly increase medical costs for discharged cancer center patients, including higher hospitalization costs and greater deficits under…
CAR-T therapy for B-cell malignancies has transformed treatment but carries risks like B-cell aplasia and cytokine release syndrome. New approaches aim to improve safety while…
Reviews indicate that while CAR-T therapy is established for B-cell malignancies, there are currently no specific outcomes or safety data available for its use in pancreatic…
Morning timing of immune checkpoint infusions is linked to better survival in metastatic non-small cell lung cancer, while other new drugs like magrolimab have not shown clear…
Cancer research is producing new treatments for autoimmune diseases by adapting cell therapies like CAR-T cells and targeting shared inflammatory pathways such as IRAK4 and…
In rare cancers treated with nivolumab plus ipilimumab, having a larger tumor burden at the start of treatment is linked to shorter overall survival.
A nurse-led music intervention shows early promise for reducing feelings of cognitive impairment in colorectal cancer patients, though it is not yet proven for all cancer types.
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.